• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法舒地尔通过刺激趋化因子 CXCL14/BRAK 的分泌来抑制纤维肉瘤的生长。

Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.

机构信息

Department of Clinical Care Medicine, Division of Pharmacology and ESR Laboratories, Kanagawa Dental College, Kanagawa, Japan.

出版信息

J Pharmacol Sci. 2012;120(3):241-9. doi: 10.1254/jphs.12177fp. Epub 2012 Oct 26.

DOI:10.1254/jphs.12177fp
PMID:23099322
Abstract

We previously reported that chemokine CXCL14/BRAK (BRAK) has antitumor activity in several carcinoma cells indicating that BRAK secretion suppresses carcinoma cells. Ras-homologous small GTPase (RhoA) and Rho-associated coiled-coil-containing protein kinase (ROCK) are important regulators of secretory processes, and activation of the RhoA/ROCK signaling pathway stimulates tumor invasion and metastasis. We investigated the effects of fasudil, a specific ROCK inhibitor, on BRAK secretion and tumor progression in mesenchymal fibrosarcoma cells (MC57). We demonstrated the antitumor activity of secreted BRAK using MC57 transplantation of BRAK in overexpressed transgenic mice. Further, to eliminate the influence of change in the mRNA expression of endogenous BRAK, we produced stable MC57 cell lines expressing BRAK (MC57-BRAK) or mock vector (MC57-MOCK). Fasudil significantly increased BRAK secretion by MC57-BRAK cells in a dose-dependent manner. To determine the effect of fasudil on tumor growth, MC57-BRAK and MC57-MOCK cells were transplanted into wild-type mice. Fasudil treatment suppressed tumor growth only in mice that had received MC57-BRAK cell transplants. These results indicate that fasudil inhibits fibrosarcoma growth by stimulating BRAK secretion and suggests that fasudil therapy might have clinical efficacy.

摘要

我们之前报道趋化因子 CXCL14/BRAK(BRAK)在几种癌细胞中具有抗肿瘤活性,表明 BRAK 的分泌抑制了癌细胞。Ras 同源小 GTP 酶(RhoA)和 Rho 相关卷曲螺旋蛋白激酶(ROCK)是分泌过程的重要调节剂,RhoA/ROCK 信号通路的激活刺激肿瘤侵袭和转移。我们研究了 Rho 激酶(ROCK)特异性抑制剂法舒地尔对间充质纤维肉瘤细胞(MC57)中 BRAK 分泌和肿瘤进展的影响。我们使用过表达 BRAK 的 MC57 移植的转基因小鼠证实了分泌的 BRAK 的抗肿瘤活性。此外,为了消除内源性 BRAK 的 mRNA 表达变化的影响,我们产生了表达 BRAK(MC57-BRAK)或 mock 载体(MC57-MOCK)的稳定 MC57 细胞系。法舒地尔以剂量依赖性方式显著增加 MC57-BRAK 细胞中 BRAK 的分泌。为了确定法舒地尔对肿瘤生长的影响,将 MC57-BRAK 和 MC57-MOCK 细胞移植到野生型小鼠中。法舒地尔治疗仅抑制接受 MC57-BRAK 细胞移植的小鼠的肿瘤生长。这些结果表明,法舒地尔通过刺激 BRAK 分泌抑制纤维肉瘤生长,并表明法舒地尔治疗可能具有临床疗效。

相似文献

1
Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.法舒地尔通过刺激趋化因子 CXCL14/BRAK 的分泌来抑制纤维肉瘤的生长。
J Pharmacol Sci. 2012;120(3):241-9. doi: 10.1254/jphs.12177fp. Epub 2012 Oct 26.
2
Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma.法舒地尔是一种Rho激酶抑制剂,通过在头颈部鳞状细胞癌中诱导CXCL14/BRAK来抑制肿瘤生长。
Biomed Res. 2014;35(6):381-8. doi: 10.2220/biomedres.35.381.
3
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.Rho激酶抑制剂法舒地尔可抑制人类和大鼠肿瘤模型中的肿瘤进展。
Mol Cancer Ther. 2006 Sep;5(9):2158-64. doi: 10.1158/1535-7163.MCT-05-0440.
4
Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.Rho 激酶抑制剂法舒地尔在体外和体内抑制神经胶质细胞瘤细胞系的进展。
Cancer Biol Ther. 2010 Jun 1;9(11):875-84. doi: 10.4161/cbt.9.11.11634. Epub 2010 Jun 26.
5
Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected].趋化因子 CXCL14/BRAK 转基因小鼠抑制癌移植细胞的生长。[已更正]
Transgenic Res. 2010 Dec;19(6):1109-17. doi: 10.1007/s11248-010-9384-7. Epub 2010 Mar 24.
6
Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo.Rho 激酶抑制剂法舒地尔抑制体外和体内 B16 小鼠黑素瘤细胞的血管生成拟态。
Mol Cancer Ther. 2015 Jul;14(7):1582-90. doi: 10.1158/1535-7163.MCT-14-0523. Epub 2015 May 1.
7
RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.法舒地尔对RhoA/ROCK通路的抑制作用可在体外抑制U2OS骨肉瘤细胞的血管生成拟态。
Anticancer Drugs. 2017 Jun;28(5):514-521. doi: 10.1097/CAD.0000000000000490.
8
Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.肿瘤抑制趋化因子 BRAK/CXCL14 的表达降低了 HSC-3 舌鳞癌细胞的迁移率,并刺激了其在体外与胶原蛋白的黏附以及长形黏着斑的形成。
Cell Biol Int. 2010 Apr 1;34(5):513-22. doi: 10.1042/CBI20090108.
9
Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.盐酸法舒地尔水合物,一种Rho激酶抑制剂,通过JNK和ERK1/2信号通路抑制5-羟色胺诱导的肺动脉平滑肌细胞增殖。
Pharmacology. 2009;83(2):67-79. doi: 10.1159/000178814. Epub 2008 Dec 4.
10
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.靶向RhoA/ROCK信号通路可改善糖尿病肾病的进展,且与血糖控制无关。
Diabetes. 2008 Mar;57(3):714-23. doi: 10.2337/db07-1241. Epub 2007 Dec 14.

引用本文的文献

1
Cancer as a biophysical disease: Targeting the mechanical-adaptability program.癌症作为一种生物物理疾病:靶向机械适应性程序。
Biophys J. 2022 Oct 4;121(19):3573-3585. doi: 10.1016/j.bpj.2022.04.039. Epub 2022 May 3.
2
The Chemokine CXCL14-like Immunoreactivity Co-exists with Somatostatin, but not NPY in the Rat Dorsal Horn and Has Intimate Association with GABAergic Neurons in the Lateral Spinal Nucleus.趋化因子CXCL14样免疫反应性与生长抑素共存于大鼠背角,但与神经肽Y不共存,且与脊髓外侧核中的γ-氨基丁酸能神经元密切相关。
Acta Histochem Cytochem. 2020 Oct 29;53(5):121-129. doi: 10.1267/ahc.20-00004. Epub 2020 Oct 20.
3
C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression.
C-X-C 基序趋化因子配体 14 是肿瘤进展的独特多功能调节剂。
Int J Mol Sci. 2019 Apr 16;20(8):1872. doi: 10.3390/ijms20081872.
4
Autophagy Inhibition Stimulates Apoptosis in Oesophageal Squamous Cell Carcinoma Treated with Fasudil.自噬抑制增强法舒地尔治疗食管鳞状细胞癌的凋亡作用。
J Cancer. 2018 Feb 28;9(6):1050-1056. doi: 10.7150/jca.23388. eCollection 2018.
5
CXCL14-like Immunoreactivity Exists in Somatostatin-containing Endocrine Cells, and in the Lamina Propria and Submucosal Somatostatinergic Nervous System of Mouse Alimentary Tract.CXCL14样免疫反应性存在于含生长抑素的内分泌细胞、小鼠消化道固有层和黏膜下生长抑素能神经系统中。
Acta Histochem Cytochem. 2017 Dec 26;50(6):149-158. doi: 10.1267/ahc.17015. Epub 2017 Nov 23.